Cost-Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Versus Lower-Valent Alternatives in Filipino Infants

被引：0
|
作者：
Rajeev Dhere
Vistasp Sethna
Hitesh Malviya
Rajeshwari Adhiseshan
机构：
[1] Serum Institute of India Private Limited,
来源：
Infectious Diseases and Therapy | 2022年 / 11卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1297 / 1299
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF SWITCHING FROM THE 10-VALENT TO THE 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN SWEDEN
    Wasserman, M.
    Dorange, A. C.
    Palmborg, A.
    McDade, C.
    Wilson, M.
    Horn, E.
    VALUE IN HEALTH, 2022, 25 (01) : S110 - S110
  • [42] COST-EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT CONJUGATE (PCV13) AND 23-VALENT (PPV23) POLYSACCHARIDE PNEUMOCOCCAL VACCINES FOR ADULTS IN SWEDEN
    Dorange, A.
    Nyman, L.
    VALUE IN HEALTH, 2016, 19 (03) : A216 - A217
  • [43] COST-EFFECTIVENESS ANALYSIS OF THE PEDIATRIC 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE COMPARED TO LOWER-VALENT ALTERNATIVES IN ARGENTINA
    Ta, A.
    Mac Mullen, M.
    Freigofaite, D.
    Huang, L.
    Waren, S.
    Carballo, C.
    Rey-Ares, L.
    VALUE IN HEALTH, 2023, 26 (12) : S199 - S199
  • [44] COST-EFFECTIVENESS OF SWITCHING STRATEGIES FROM A 7-VALENT TO A 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE
    Claes, C.
    Mittendorf, T.
    Kuchenbecker, U.
    Rose, M.
    Reinert, R. R.
    VALUE IN HEALTH, 2009, 12 (07) : A425 - A425
  • [45] Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to the 10-Valent Pneumococcal Conjugate Vaccine (PCV10) in Italy
    Ansaldi, Filippo
    Pugh, Sarah
    Amicizia, Daniela
    Di Virgilio, Roberto
    Trucchi, Cecilia
    Orsi, Andrea
    Zollo, Alessandro
    Icardi, Giancarlo
    PATHOGENS, 2020, 9 (02):
  • [46] Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus "no vaccination" and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine
    Gouveia, Miguel
    Jesus, Goncalo
    Ines, Monica
    Costa, Joao
    Borges, Margarida
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2019, 15 (04) : 850 - 858
  • [47] Estimating the Clinical and Economic Impact of Switching from the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) to Higher-Valent Options in Greek Infants
    Warren, Sophie
    Barmpouni, Myrto
    Kossyvaki, Vasiliki
    Gourzoulidis, George
    Perdrizet, Johnna
    VACCINES, 2023, 11 (08)
  • [48] Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infants
    Zhou, Hua
    He, Jinchun
    Wu, Bin
    Che, Datian
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (06) : 1444 - 1452
  • [49] Cost-effectiveness analysis of pneumococcal conjugate vaccine 13-valent in older adults in Colombia
    Jaime E Ordóñez
    John J Orozco
    BMC Infectious Diseases, 14
  • [50] Real-life effectiveness data on prevention OF COPD and asthma exacerbations with 13-valent pneumococcal conjugate vaccine (PCV13)
    Mezquita, Miguel Angel Hernandez
    Boscam, Alexis Morales
    Sierra, Vanesa Hidalgo
    Ballesteros, Mercedes Sobrino
    Ferrero, Miguel Barrueco
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
12345